Kinetics for Drug Discovery: an industry-driven effort to target drug residence time DA Schuetz, WEA de Witte, YC Wong, B Knasmueller, L Richter, DB Kokh, ... Drug discovery today 22 (6), 896-911, 2017 | 198 | 2017 |
Multiple binding sites for small-molecule antagonists at the CC chemokine receptor 2 AJM Zweemer, I Nederpelt, H Vrieling, S Hafith, MLJ Doornbos, ... Molecular pharmacology 84 (4), 551-561, 2013 | 72 | 2013 |
Characterization of 12 GnRH peptide agonists–a kinetic perspective I Nederpelt, V Georgi, F Schiele, K Nowak‐Reppel, ... British journal of pharmacology 173 (1), 128-141, 2016 | 44 | 2016 |
Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients WEA de Witte, YC Wong, I Nederpelt, LH Heitman, M Danhof, ... Expert opinion on drug discovery 11 (1), 45-63, 2016 | 38 | 2016 |
Kinetic binding and activation profiles of endogenous tachykinins targeting the NK1 receptor I Nederpelt, D Bleeker, B Tuijt, AP IJzerman, LH Heitman Biochemical Pharmacology 118, 88-95, 2016 | 20 | 2016 |
Persistent GnRH receptor activation in pituitary αT3-1 cells analyzed with a label-free technology I Nederpelt, RD Vergroesen, AP IJzerman, LH Heitman Biosensors and Bioelectronics 79, 721-727, 2016 | 18 | 2016 |
From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action I Nederpelt, M Kuzikov, WEA de Witte, P Schnider, B Tuijt, S Gul, ... Scientific Reports 7 (1), 14169, 2017 | 14 | 2017 |
Kinetic profile of neuropeptide–receptor interactions I Nederpelt, J Bunnik, AP IJzerman, LH Heitman Trends in neurosciences 39 (12), 830-839, 2016 | 12 | 2016 |
Time is of the essence-investigating kinetic interactions between drug, endogenous I Nederpelt drug discovery & development 12 (4), 488-96, 2009 | 1 | 2009 |